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Background: The pathophysiology of reversible cerebral vasoconstriction syndrome (RCVS) remains elusive. Endothelial
dysfunction might play a role, but direct evidence is lacking. This study aimed to explore whether patients with RCVS
have a reduced level of circulating circulating endothelial progenitor cells (EPCs) to repair the dysfunctional endothelial
vasomotor control.
Methods: We prospectively recruited 24 patients with RCVS within one month of disease onset and 24 healthy age- and
sex-matched controls. Flow cytometry was used to quantify the numbers of circulating EPCs, defined as KDR+CD133+,
CD34+CD133+, and CD34+KDR+ double-positive mononuclear cells. The Lindegaard index, an index of vasoconstriction,
was calculated by measuring the mean flow velocity of middle cerebral arteries and distal extracranial internal
carotid arteries via color-coded sonography on the same day as blood drawing. A Lindegaard index of 2 was
chosen as the cutoff value for significant vasoconstriction of middle cerebral arteries based on our previous study.
Results: Patients with RCVS had a reduced number of CD34+KDR+ cells (0.009 ± 0.006% vs. 0.014 ± 0.010%, p = 0.031)
but not KDR+CD133+ cells or CD34+CD133+ EPCs, in comparison with controls. The number of CD34+KDR+ cells was
inversely correlated with the Lindegaard index (rs = −0.418, p = 0.047). Of note, compared to controls, patients with a
Lindegaard index > 2 (n = 13) had a reduced number of CD34+KDR+ cells (0.007 ± 0.005% vs. 0.014 ± 0.010%, p = 0.010),
but those with a Lindegaard index≤ 2 did not.
Conclusions: Patients with RCVS had reduced circulating CD34+KDR+ EPCs, which were correlated with the severity of
vasoconstriction. Endothelial dysfunction might contribute to the pathogenesis of RCVS.
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Reversible cerebral vasoconstriction syndrome (RCVS) is
clinical-radiological syndrome characterized by recurrent
thunderclap headaches and reversible segmental vaso-
constrictions of cerebral arteries [1,2]. Large case series
have demonstrated that RCVS is not uncommon [3-5],
but rather an under-recognized clinical emergency [6].
Patients with RCVS exhibit substantial risks of devastating
complications such as posterior reversible encephalopathy
syndrome (PRES), ischemic stroke, and intracranial* Correspondence: jlfuh@vghtpe.gov.tw; sjwang@vghtpe.gov.tw
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in any medium, provided the original work is phemorrhages (including cortical subarachnoid, intracerebral,
and even subdural hemorrhage) [3-5,7-9].
RCVS can be either idiopathic or secondary. For some
secondary RCVS cases, the use of cocaine or marijuana
is the inciting factor responsible for the pathogenesis.
However, the pathogenesis of idiopathic RCVS is enig-
matic. Sympathetic overactivity [10], oxidative stress [11]
and genetic predisposition [12] might play certain roles.
We suspect that endothelial dysfunction in RCVS is also
highly plausible because both sympathetic overactivity
and oxidative stress are detrimental to the endothelium
[13-15]. Recent studies showed that bone marrow-derived
endothelial progenitor cells (EPCs) are the main source
that contributes to the regeneration and maintenance of
the endothelium [16,17]. The number of circulating EPCsOpen Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
Chen et al. The Journal of Headache and Pain 2014, 15:82 Page 2 of 7
http://www.thejournalofheadacheandpain.com/content/15/1/82has been reported to be a surrogate biologic marker of
vascular function and to correlate inversely with the endo-
thelial repair capacity and cardiovascular risks [17-19]. We
hypothesized that patients with RCVS might have decreased
circulating EPCs during the course of vasoconstriction.
Methods
Ethics
The study protocol was approved by the Institutional
Review Board of Taipei Veterans General Hospital. All
participants provided written informed consent before
entering the study. All clinical investigations were con-
ducted according to the principles expressed in the
Declaration of Helsinki. The corresponding authors had
full access to all of the data in the study and had final
responsibility for the decision to submit the results for
publication.
Participants and clinical settings
Patients with RCVS were recruited from the Neurology
Department of Taipei Veterans General Hospital, a 2,909-
bed national medical center located in Taipei City from
2011 to 2013. Age- and sex-matched volunteer partici-
pants who had neither headache history nor severe medical
illness were recruited as normal controls. The inclusion
criteria for the participants (both patients and controls)
were the following: (1) age between 20 and 65 years, and
(2) subjects could fully understand the purpose of the re-
search and voluntarily join the study. Because many intrin-
sic or exogenous factors could influence the number of
circulating EPCs, we applied very strict exclusion criteria
and selectively enrolled matched controls to eliminate the
influence of these confounders. Subjects were excluded
if they met the following criteria: (1) had a smoking history,
(2) had a major systemic illness such as uncontrolled hyper-
tension (systolic blood pressure > 160 mmHg, diastolic
blood pressure > 100 mmHg) at baseline, diabetes mellitus,
cardiovascular or cerebrovascular disease, chronic hepatic
or renal disease, or malignancies, (3) used illicit drugs;
or (4) women who were pregnant or within 3 months
postpartum. Subjects with a history of migraine and grade
1 hypertension (systolic blood pressure 140–159 mmHg,
diastolic blood pressure 90–99 mmHg) were permitted to
enroll because some patients with RCVS may have mi-
graine and hypertension.
The diagnosis of RCVS was based on the following
criteria: (1) at least two acute-onset severe headaches
(thunderclap headaches), with or without focal neurological
deficits; (2) vasoconstrictions demonstrated on magnetic
resonance angiography (MRA); (3) reversibility of vaso-
constrictions, as demonstrated by at least one follow-up
MRA within 3 months; and (4) aneurysmal subarachnoid
hemorrhage or other intracranial disorders were ruled out
by appropriate investigations, but cortical subarachnoidhemorrhage in RCVS was allowed. The diagnostic criteria
were adapted from the criteria of “benign (or reversible)
angiopathy of the central nervous system” proposed by the
International Classification of Headache Disorders, second
edition (ICHD-2) (Code 6.7.3) [20] with the exception of
the duration criterion D as well as the essential diagnostic
elements of RCVS proposed by Calabrese et al. [1]. In
this study, only patients with idiopathic RCVS within
one month of headache onset were eligible to minimize
potential confounders.
Clinical evaluations
Basic demographic information and anthropometric mea-
surements including height, body weight, and body mass
index (BMI) [21] were collected. All enrolled subjects re-
ceived comprehensive clinical and neurological examina-
tions, and provided detailed medical, headache, and drug
histories upon entering the study. Lipid profiles were ob-
tained from general serological surveys. Diagnostic investi-
gations including the first MRA, transcranial color-coded
sonography and/or spinal taps were performed within the
first two days after the patient was seen. Control subjects
did not receive neuroimaging studies. The protocols have
been reported previously [3,7,8]. In brief, brain MRI, MRA
and MR venography (MRV) studies were performed with
a 3-Tesla MR scanner. Intracranial lesions were carefully
evaluated with adequate MR sequences, for example,
subarachnoid hemorrhage with susceptibility weighted
imaging (SWI) and intracranial aneurysms with three-
dimensional time-of flight (TOF) MRA. Sequential MRAs
were performed in all subjects with RCVS until the
normalization of vasoconstrictions. The mean flow velocity
of the major cerebral arteries was detected by transcranial
color-coded sonography and recorded; the protocols were
detailed elsewhere [7]. The following data were analyzed:
mean flow velocity of middle cerebral artery (MCA)
(VMCA) and the Lindegaard index (LI), which is calcu-
lated by dividing the VMCA by the mean flow velocity of
the ipsilateral distal extracranial internal carotid artery.
The LI was selected to evaluate the vasoconstrictions to
avoid possible misreading of hyperemia as vasospasm. For
computational purposes, the average VMCA and LI derived
from the bilateral MCAs in each patient were calculated.
We analyzed only VMCA and LI because MCA is the most
widely studied and validated vessel for vasoconstrictions
using transcranial color-coded sonography (TCCS) and
there have been no validated sonographic criteria of vaso-
constrictions for the other cerebral vessels with adequate
sensitivity [7]. In addition, our previous studies showed a
good correlation of VMCA and LI with the severity of vaso-
constrictions detected by MRA.
Because the severity of vasoconstriction of the MCA
could vary between patients at the time of blood sampling,
we further stratified the patients according to their LI
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the upper limit of our normal controls, was chosen to
stratify the patients into two groups: those having either
significant or insignificant vasoconstrictions of the MCA.
An LI value of 3 was also used to evaluate whether pa-
tients at risk of ischemic complications [7] could have
lower EPCs. Of note, the cut-off values of LI used here
were based on our previous study in RCVS patients
using TCCS [7] and should not be translated to the same
severity of vasopasm in SAH based on studies using trans-
cranial Doppler (TCD) [22]. In patients with SAH, the LI
is disproportionately amplified because of low extracranial
ICA flow velocity due to cerebral hypoperfusion caused
by increased intracranial pressure (IICP) [22,23], while pa-
tients with RCVS usually have normal ICP [1-3]. Patients
with RCVS who fulfilled the mild vasospasm criteria for
SAH already had high risks of developing PRES (75%) or
ischemic stroke (50%) [7].
Flow cytometric analysis of circulating EPCs
The flow cytometric analysis of circulating EPCs was
performed based on our previously established methods
[24]. Peripheral blood was collected from the antecubital
vein on the same day of transcranial color-coded sonog-
raphy, before administration of any therapeutics. The sam-
ples were processed immediately after blood drawing. A
volume of 100 μL blood was incubated for 15 minutes
in the dark with monoclonal antibodies against human
kinase insert domain receptor (KDR; R&D, Minneapolis,
MN, USA) followed by phycoerythrin (PE)-conjugated
secondary antibody, with the fluorescein isothiocyanate
(FITC)-labeled monoclonal antibodies against human CD45
(Becton Dickinson, Franklin Lakes, NJ, USA), with the
PE-conjugated monoclonal antibody against human CD133
(Miltenyi Biotec, Germany), and with FITC-conjugated
or PE-conjugated monoclonal antibodies against human
CD34 (Serotec, Raleigh, NC, USA). Isotype-identical anti-
bodies were used as controls (Becton Dickinson, Franklin
Lakes, NJ, USA). After incubation, cells were lysed, washed
with phosphate-buffered saline (PBS), and fixed in 2%
paraformaldehyde before analysis. Each analysis included
100,000 events. Flow cytometry was used to quantify the
numbers of circulating EPCs defined as KDR+CD133+,
CD34+CD133+, and CD34+KDR+ double-positive mono-
nuclear cells (Additional file 1: Figure S1). To assess the
reproducibility of the EPC measurements, circulating
EPCs were measured from two separate blood samples
in 20 subjects (10 controls and 10 patients each). Mature
circulating endothelial cells, which are generally recog-
nized as cells expressing endothelial markers (CD 144,
CD 146, vWF, VEGFR-2) in the absence of hematopoietic
(CD 14, CD 45) and progenitor (CD 34, CD 133) markers
(despite the lack of a clear concensus on their phenotypic
definitions) [25,26], were excluded with this method.Statistics
Descriptive statistics are presented as the mean ± standard
deviation or as the number (percentage). For normally
distributed variables, continuous ones were compared
by the Student’s t-test, and categorical ones were com-
pared by the Chi-square or Fisher exact tests. For variables
that don’t have a normal distribution, Kruskal-Wallis test
and Mann–Whitney U test were used as appropriate.
For correlations between EPC counts with other variables,
Spearman correlation coefficient rs was applied because
EPC counts were not normally distributed (by Shapiro-Wilk
test). All calculated p-values were two-tailed. Statistical
significance was defined as p < 0.05. Because there was collin-
earity between the number of KDR+CD133+, CD34+CD133+,
and CD34+KDR+ cells (the correlation coefficients were
0.666 for CD34+CD133+ and CD34+KDR+ cells (p < 0.001),
0.735 for KDR+CD133+ and CD34+CD133+ cells (p < 0.001),
and 0.570 for KDR+CD133+ and CD34+KDR+ cells
(p < 0.001)), corrections for multiple comparisons were not
applied in this study. All analyses were performed with
the IBM SPSS Statistics software package, version 18.0.
Results
Participants and their characteristics
During the two-year study period, we prospectively re-
cruited 31 patients with RCVS. After excluding one pa-
tient with a previous history of intracerebral hemorrhage,
one patient with previous cerebral infarction, two patients
who used psueodephedrine, one patient who had a history
of marijuana use, one patient who was postpartum, and
one heavy smoker, 24 patients were eligible for study.
Another 24 age- and sex-matched controls were recruited
during the study period. There was no difference in the
demographics, BMIs, medical illnesses, and serum choles-
terol levels between the two groups (Table 1). Most of
the patients (91.7%) had identifiable triggers for their
thunderclap headaches, with defecation (58.3%) and bath-
ing (29.2%) being the most common. The cerebrospinal
fluid was studied in 12 (50%) patients, and their results
were all normal.
Neuroimaging findings
None of the patients had posterior reversible encephalop-
athy syndromes, ischemic stroke, intracerebral hemorrhage
or intracranial arterial dissection on the initial or follow-up
MR studies, but one patient had cortical subarachnoid
hemorrhage confined to right anterior high frontal cor-
tex without identifiable aneurysm. None of the patients
had aneurysmal subarachnoid hemorrhage in consecutive
MR studies.
EPC measurements
The blood samples were taken at a mean of 5.4 ± 3.7 days
(range 2–13) after headache onset. Of the 20 subjects
Table 1 Basic demongraphics, body mass index, and
medical illness of participants
Controls(n = 24) RCVS(n = 24) P value
Age, y (mean ± SD) 45.0 ± 11.9 48.8 ± 9.5 0.229
Gender (M/F) 4/20 4/20 1.000
Menopause, n (%) 6 (12%) 7 (14%) 0.906
Body mass index (kg/m2) 25.3 ± 1.7 24.0 ± 3.0 0.525
Hypertension, n (%) 0 (0%) 1 (4.2%) 0.312
Diabetes, n (%) 0 (%) 0 (0%) 1.000
Coronary artery disease,
n (%)
0 (%) 0 (0%) 1.000
Migraine, n (%) 2 (8.3%) 4 (16.7%) 0.663
Cholesterol (mg/dL) 193.6 ± 35.3 183.7 ± 28.7 0.370
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correlation between the two measurements suggesting
high reproducibility (CD34+CD133+: rs = 0.973, p < 0.001;
CD34+KDR+: rs = 0.972, p < 0.001; and KDR+CD133+: rs =
0.976, p < 0.001). There were no correlations between the
EPC counts and age, gender, BMI, menopausal status,
migraine, hypertension, or serum cholesterol level.
In comparison to the controls, patients with RCVS had
reduced numbers of CD34+KDR+ cells (0.009 ± 0.006% vs.
0.014 ± 0.010%, p = 0.031), but they had no reduction in
KDR+CD133+ cells (0.031 ± 0.015% vs. 0.039 ± 0.020%,
p = 0.176) or CD34+CD133+ EPCs (0.045 ± 0.028% vs.
0.060 ± 0.041%, p = 0.140). The EPC counts in patients with
comorbid migraine (n = 4) did not differ from that in
patients without comorbid migraine (n = 20) (CD34+KDR+
cells (0.007 ± 0.006% vs. 0.009 ± 0.006%, p = 0.751),
KDR+CD133+ cells (0.027 ± 0.010% vs. 0.032 ± 0.015%,
p = 0.642), CD34+CD133+ EPCs (0.042 ± 0.007% vs.
0.045 ± 0.030%, p = 0.781)).
In comparison with the controls, patients with an LI > 2
(n = 13) had fewer CD34+KDR+ cells (0.007 ± 0.005% vs.
0.014 ± 0.010%, p = 0.010), but there was no difference in
the number of KDR+CD133+ cells (0.032 ± 0.014% vs.
0.039 ± 0.020%, p = 0.186) or CD34+CD133+ EPCs (0.042 ±
0.023% vs. 0.060 ± 0.041%, p = 0.087).The EPC counts of
patients with LI ≤ 2 did not differ from those of the controls
(CD34+KDR+ cells: 0.012 ± 0.006% vs. 0.014 ± 0.010%,
p = 0.392; KDR+CD133+ cells: 0.036 ± 0.016% vs. 0.039 ±
0.020%, p = 0.404; CD34+CD133+ cells: 0.052 ± 0.032% vs.
0.060 ± 0.041%, p = 0.534.) (Figure 1)
In patients with LI > 3 (n = 3), the trend was similar:
Their CD34+KDR+ cell counts were lower than the con-
trols (0.006 ± 0.002% vs. 0.014 ± 0.010%, p = 0.015), but
there was no difference in the numbers of KDR+CD133+
cells (0.023 ± 0.008% vs. 0.039 ± 0.020%, p = 0.070) or
CD34+CD133+ EPCs (0.032 ± 0.012% vs. 0.060 ± 0.041%,
p = 0.054).Correlations between EPCs and clinical variables
The number of CD34+KDR+ cells was negatively correlated
with the LI (rs = −0.418, p = 0.047) (Figure 2), whereas
there was no significant correlation of LI with the number
of KDR+CD133+ (rs = −0.265, p = 0.221) or CD34+CD133+
cells (rs = −0.207, p = 0.344). None of the other clinical var-
iables such as triggers (including defecation, bathing, exer-
tion, cough, rage, or sex) or the number and duration of
thunderclap headaches before blood drawing had signifi-
cant correlations with the EPCs counts (data not shown).
Discussions
Our study demonstrated that patients with RCVS had
reduced circulating CD34+KDR+ EPCs in comparison with
controls, especially in those with more severe vasocon-
strictions (LI > 2) and those at risk of ischemic complica-
tions (LI > 3). The number of CD34+KDR+ EPCs was
negatively correlated with the severity of vasoconstrictions
evaluated with the LI. In contrast, the KDR+CD133+ and
CD34+CD133+ EPCs did not show any associations with
RCVS.
Circulating EPCs are capable of patching sites of de-
nuding injury, and they serve as a cellular reservoir for
the replacement of dysfunctional endothelium [27,28].
However, it is unclear which antigenic profiles best iden-
tify progenitor cells with the potential for endothelial
repair [29]. Cells expressing CD34 (an adhesion molecule
expressed on hematopoietic stem cells) and KDR (a type 2
vascular endothelial growth factor receptor that indi-
cates early endothelial differentiation) might be the main
constituent of the circulating EPCs responsible for re-
endothelialization [30]. The identification of fewer circu-
lating CD34+KDR+ EPCs was consistent with our hypoth-
esis that patients with RCVS had a reduced capacity for
endothelial repair. The inverse correlation between the
CD34+KDR+ EPC count and the severity of vasoconstric-
tion further supports the hypothesis that the reduced
endothelial repair capability might be associated with the
overwhelmed vasomotor control in RCVS. The reason
why the KDR+CD133+ and CD34+CD133+ EPCs were
not correlated with severity of vasoconstrictions was
unknown, but these findings might suggest that not all the
EPC phenotypes were associated with vasomotor control.
It is unclear whether there is a causal relationship be-
tween reduced EPC counts and vasoconstrictions in RCVS.
Whether patients with RCVS have already had reduced cir-
culating EPCs before disease onset could never be proved
since it’s almost impossible to have pre-morbid EPC meas-
urement. We put forth the following hypotheses. First, it is
possible that when an unknown insult ignites the vicious
cycle of sympathetic overactivity [10] and oxidative stress
[11], which damages the endothelium of the cerebral
vasculature, EPCs will be mobilized from the bone marrow
into the circulation to repair the endothelial damage.
Figure 1 Comparison of the numbers of endothelial progenitor
cells between patients with reversible cerebral vasoconstriction
syndrome and controls. (column: mean, error bars: standard errors).
RCVS: reversible cerebral vasoconstriction syndrome; LI: Lindegaard
index.
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capacity of EPC mobilization, they are likely to develop
more severe vasoconstriction. In contrast, patients with
sufficient EPCs might have less severe vasoconstrictions.
Second, sympathetic overactivity and oxidative stress may
accelerate the consumption or senescence of circulating
EPCs [31,32], which could further hamper the numbers
and function of EPCs. However, this was purely specula-
tive because we did not perform functional assays on EPCs
in this study. Previous studies have shown that headache
disorders such as migraine or cluster headache could be
modulated by immunological cells that migrate from
peripheral blood circulation into central nervous system,
via an altered expression of adhesion molecules and
chemotactic cytokines. Although mechanistically differ-
ent, this neuroimmunological interplay might serve as a
model for us to envision the mechanism of EPCs in
RCVS [33,34].
Our study has limitations. First, to eliminate the influ-
ence of potential confounders that might interfere EPC
counts, we applied very strict exclusion criteria and select-
ively enrolled matched controls. Hence, it is not possible
to conclude whether the study results are generalizable to
patients who have multiple vascular risk factors or obvious
secondary causes of RCVS, such as illicit drug users. In
addition, the number of participants was limited in this
study partially due to the exclusion and matching criteria.
However, considering the prevalence of RCVS, the possible
interassay variability during the prolonged study duration
(which could be due to machines, operators, and reagents,
etc.), and the significant study results, we believe that theFigure 2 Correlation between the numbers of CD34+KDR+
endothelial progenitor cells and Lindegaard index.
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purposes. Finally, as mentioned above, we did not per-
form functional assays on EPCs. Further mechanistic
approaches are required.
Conclusions
Patients with RCVS had reduced circulating CD34+KDR+
EPCs, which were inversely correlated with the severity
of vasoconstrictions. A reduced capacity of circulating
EPCs to repair dysfunctional endothelial vasomotor con-
trol might contribute to the pathogenesis of vasoconstric-
tions in patients with RCVS. The potential of therapies
targeting the restoration of endothelial function deserves
exploration.
Additional file
Additional file 1: Figure S1. Representative flow cytometric analysis for
quantifying the number of circulating endothelial progenitor cells (EPCs).
Mononuclear cells were gated by forward/sideward scatter (FSC/SSC), and
the numbers of circulating EPCs were defined as CD34+KDR+, CD34+CD133+,
and KDR+CD133+ cells respectively. (A) Patients with reversible cerebral
vasoconstriction syndrome, (B) Controls.
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